# S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas

> **NCT00217620** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 51 (actual)

## Conditions studied

- Sarcoma

## Interventions

- **DRUG:** sorafenib

## Key facts

- **NCT ID:** NCT00217620
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2008-04
- **Final completion:** 2012-09
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2014-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00217620

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00217620, "S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00217620. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*